Vesugen (Lys-Glu-Asp): Evidence Status of the Family's Structural Hub

Vesugen is the KED tripeptide that three other catalog compounds extend by a single residue — and it has no published study naming it. What is established, and the contrast with Pancragen.

vesugen bioregulator khavinson Lys-Glu-Asp KED tripeptide vascular evidence status

Key Research Findings

  • Vesugen is the tripeptide Lys-Glu-Asp (KED), C15H26N4O8, 390.39 g/mol, classified as vascular-associated.
  • It is the structural hub of the family: Prostamax, Livagen and Pancragen are each KED plus one residue.
  • No PubMed-indexed study names Vesugen.
  • The vascular peptide paper often cited for it concerns a different preparation, not KED under this name.
  • Pancragen (KED + Trp) has six papers; Vesugen has none — one residue apart.
  • No amount is established for any species.

What Vesugen Is

Vesugen is a synthetic tripeptide, Lys-Glu-Asp (KED), C15H26N4O8, 390.39 g/mol. Within the peptide bioregulator family it is classified as vascular-associated.

KED is the structural hub of this family. Three other catalog compounds are the same tripeptide with one residue added: Prostamax is KED + proline, Livagen is KED + alanine, and Pancragen is KED + tryptophan. That makes Vesugen the natural reference point for any question about how a single added residue changes behaviour.

Research use only. Supplied for laboratory research. Not for human or veterinary use. No marketing authorisation exists and no therapeutic claim is made.

What the Published Literature Contains

No PubMed-indexed study names Vesugen in its title. There is no compound-specific work establishing a biological effect, a mechanism tied to this sequence, a safety profile, or an amount for any species.

The class-level literature describes short peptides generally: the systematic review of peptide regulation of gene expression (Khavinson et al., Molecules 2021, PMID 34834147), and work on a vascular peptide preparation and microvascular density in aged rat brain cortex (Sokolova et al., Bull Exp Biol Med 2016, PMID 27383168).

That second paper is the one most often cited as if it were a Vesugen study. It is not: it concerns a vascular peptide preparation within the same programme, not KED under this name. The distinction matters when the vascular association is being used as a premise.

The Contrast Worth Designing Around

Pancragen — KED plus a single tryptophan — has six papers naming it, including primate work. Vesugen has none. One residue separates the best-documented compound in this family from one with no compound-specific literature at all.

If the research question is whether the family's tissue assignments track sequence or are conventional labels, that pair is the cleanest available comparison.

Structure and Handling

  • Sequence. Lys-Glu-Asp (KED), tripeptide.
  • Formula. C15H26N4O8, 390.39 g/mol.
  • Form. Lyophilised powder, ≥98% purity, third-party certificate of analysis per batch.
  • Storage. Sealed vial at −20 °C, protected from light; reconstituted solution at 2–8 °C.
  • Reconstitution. Bacteriostatic water down the vial wall, never onto the powder cake. Do not shake. See the reconstitution calculator.

Do not confuse Vesugen with Vesilut: they are different molecules — Vesilut is the dipeptide Glu-Asp. For compounds with substantive published work see Vilon, Pancragen and Epithalon. Full family on the bioregulator overview.

Frequently Asked Questions

What is Vesugen?

Vesugen is a synthetic tripeptide, Lys-Glu-Asp (KED), C15H26N4O8, 390.39 g/mol, classified within the Khavinson bioregulator family as vascular-associated.

Is Vesugen the same as Vesilut?

No. They are distinct molecules. Vesugen is the tripeptide Lys-Glu-Asp; Vesilut (Vesilute, ED) is the dipeptide Glu-Asp, C9H14N2O7, 262.22 g/mol. An earlier version of this page stated they were the same compound; that was incorrect and has been corrected.

Is there published research on Vesugen?

No PubMed-indexed study names Vesugen in its title. The vascular peptide paper often cited alongside it (PMID 27383168) concerns a preparation within the same research programme, not KED under this name.

How does Vesugen relate to Prostamax, Livagen and Pancragen?

All three are KED with one residue added: Prostamax is KED plus proline, Livagen KED plus alanine, Pancragen KED plus tryptophan. Pancragen has six papers naming it including primate work; Vesugen has none — which makes the pair a clean test of whether the family tissue assignments track sequence.

What is the Vesugen dosage?

No amount is established for any species or context, because no published study on this compound reports one.

References

  1. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review Molecules (2021)
  2. Sokolova IB, Sergeev IV, Dvoretskii DP. Effects of vascular peptide bioregulator on the density of microvascular network in the brain cortex of aged rats Bulletin of Experimental Biology and Medicine (2016)
Research Use Only: This content is intended for laboratory and scientific research purposes only. It is not intended for human use, medical advice, diagnosis, or treatment. All compounds discussed are for in vitro and preclinical research contexts.